BioPsych Diagnostics, P.A. 223 East Flagler St., Suite #432 Miami, Fl. 33131 Tel: 786-548-1412

RESUME:	Richard Elias Fernandez, Ph.D.
BORN:	July 6, 1967-Santiago, Dominican Republic
PHONE:	Tel: 305-397-9094 • Fax: 786-220-7397
LANGUAGES:	English and Spanish
CITIZENSHIPS:	USA and Dominican Republic
EDUCATION:	
April 1997 Doctor of Philosophy (Ph.D.) in Clinical Psychology-Behavioral Medicine Track,	
Alliant International University/CSPP (APA-Approved), San Diego, California.	

Dissertation: Attention Shifting in Young Children with Autism: An Ecological Validation Study. Study tested neurobiological theory of attention shifting in children with autism.

August 1993 Master of Arts in Clinical Psychology, Alliant/CSPP University (APA Approved), San Diego, California.

May 1990 Bachelor of Arts with Highest Honors, Psychology, Phi Beta Kappa, Rutgers University, Newark, N.J.

## LICENSES:

2008 Florida Psychology License Number PY 7672 2001 New Jersey Psychology License Number 3958 (Inactive) 2001 New York Psychology License/Certificate Number 014654

## CLINICAL/RESEARCH/TEACHING EXPERIENCE:

April 08-Present. Clinical psychologist in private practice in Miami, Florida and Santiago, Dominican Republic. Mental status examinations and neuropsychological assessments of Flordia state disability claimants (children and adults); competency to proceed evaluations and waiver of Miranda rights for the Dade county juvenile justice system and adult criminal psychiatric population; neurocognitive assessment of US citizen applicants requring medical certificaiton of disability; parent mental health/psychological assessments for dependency court; termination of parental rights; clinical consultations at Florida State Prison and Union Correctional Institution of correctional management, disciplinary confinement and death row inmates; assessment of inmate psychological emergencies; evaluations of inmates in self-harm observation cells (SHOS) of suicidal or homicidal inmates or acute psychiatric states; referals of psychiatric inmates to crises stabilization and transitional care units; outpatient counseling of patients with general psychiatric problems; telehealth/telebehavioral inpatient consultations; neuropsychological evaluation of capital punishment inmates.

January 2011-Summer 2014. Adjunct professor of physiology of behavior and neuropsychological assessment at Albizu University, Miami, Florida. Teaching doctoral level courses in neurophysiology and neuropsychological assessments.

January 2009-December 2010. Assistant professor of clinical psychology at the Carlos Albizu University, Miami, Fl. Responsibilities included teaching of doctoral level classes; chairing student dissertation and doctoral (Psy.D.) projects; participation in university

committees (Domain C: Program Resources) for APA re-accreditation purposes; chairperson of university workgroup for the Middle States Commission of Higher Education Standard 7 (Self-Assessment) Re-accreditation.

April 08-Dec. 2008. Senior psychologist. Dade Correctional Institution Crisis Stabilization Unit (and Self-Harm Observation Cells) and Transitional Care Units, Florida City, Fl. Administrative supervision of inpatient (200 bed) psychiatric facility, and underlying personnel, including psychiatrists, nurses and behavioral health specialists (BHS), behavioral health technicians; clinical consultations of inpatient criminal psychiatric patients; clinical supervision of BHS; facilitating multi-disciplinary service teams, i.e., psychiatry, nursing, security, psychological specialists, behavioral health coaches; leading reviews of inmate individual service plans; hiring of new medical and administrative personnel; coordination of inmate referrals to correctional mental health inpatient (CMHI) transfers; facilitating interdepartmental-medical, and psychiatric programs functions; ensuring psychiatric/psychological compliance and monitoring in accordance with the health service bulletins of the Florida Department of Corrections.

June 05-Present Clinical psychologist in private practice. Diagnostic psychiatric/psychological/intellectual evaluations for federal and state disability determinations and child protective services clients as well as clients referred by the public defender's office; independent medical evaluations for personal injury cases.

February '04-May '05 Sabbatical-Traveled through Caribbean, North America, Canada, Asia.

June 01-Jan 04 Clinical psychologist in private practice in North Bergen and Newark, New Jersey. Diagnostic psychiatric/psychological/intellectual evaluations for federal and state disability determinations and child protective services clients (Division of Youth and Family Services) as well as clients referred by the public defender's office; independent medical evaluations for personal injury cases; evaluations of sexual perpetrators; child custody evaluations; expert witness testimony on parental rights termination cases; evaluations for NJ Commission for the Blind and Visually Impaired; evaluations for NJ Division of Vocational Rehabilitation; mental competency; guardianship evaluations. Consultations at Juvenile Detention Center, Kearney Prison and group homes; nursing home consultations.

Jan 98-2001 Post-doctoral intern in private practice under supervision of Joel Federbush, M.D. and Harvey Block, Ph.D. Paramus, and Union City, N.J. Providing neuropsychological and psychological consultations/assessments to the North and South Hudson County Division of Youth and Family Services and the Hudson County Urban League, North Bergen and Jersey City, New Jersey. Psychological/psychiatric assessments of individuals referred by child-protective services (Division of Youth and Family Services), assessment of dangerous and capacity to carry fire-arms; fitness for duty evaluations; child custody evaluations. Evaluations of Spanish and English-speaking court ordered evaluations.

January '00-Nov 03 Consulting clinical psychologist, Care-Plus Psychiatric Center, Inc., Paramus, NJ. Psychological evaluations of fire setters (pyromaniacs) referred by courts, probation, family services, and local psychiatric hospitals.

Jun 97-January '00 ClinForce Clinical Research Consultant/Project Manager. Pfizer

Pharmaceuticals, New York. Monitored and supervised all phases of CNS pharmacological research studies under the supervision of the associate medical director. Duties include submission of Investigational New Drug Applications to the Food and Drug Administration of Phase III and IV medical studies; assisting development of study protocols and conducting research according to Good Clinical Practices and Federal Regulations; liaison to Drug Regulatory Affairs, Clinical Research Organizations, Drug Safety Departments, Serious Adverse Events Dept., Grants & Contracting Dept., Clinical Drug Supplies, Finance Dept., and medical research sites; development of case report forms and consent forms; and assuring patient safety; medical review of psychiatric drug studies and other drug therapies. See below for listing of clinical trials.

Sept. 98-June 99 Post-doctoral intern. Straight and Narrow, Inc., Paterson, N.J. Inpatient individual/group psychotherapy, and psychological/psychiatric and neurocognitive assessments of criminal, psychoactive substance addicted patients. Patient population includes court-mandated treatment of parolees, probationers, first-time offenders, and drug-addicted mothers stipulated by the child-protective services (Work First Program). Psychological/psychiatric evaluation related to patient's capacities for parenting/caretaking of children as part of the Work First Program.

May 95-Jan. 97 Registered Psychological Assistant (Registration Number PSB22999) under supervision of Dr. Gregg Michel. San Diego, Ca. Translations for forensic psychological assessments and neuro-cognitive/personality testing of criminal inmates.

Jul. 93-Jan. 97 Consulting Clinical Research Associate, Behavioral and Medical Resources, Inc. Evaluation of psychiatric patients for pharmacological research studies. Patient assessment using neuropsychological instruments and other psychometric batteries; psychosocial evaluations. Monitored patient responses to clinical trials (Phase III-IV) medications. Central nervous system clinical trials studies conducted with anti-psychotic, anti-dementia, anti-depressants, anxiolytic, and other medications. Neurocognitive testing of Psychotic Disorder, Alzheimer's Disease, Post-Traumatic Stress Disorder, Anxiety Disorder and Major Depressive Disorder patients; administration of psychosocial rating scales; coordinating and monitoring all phases of research protocols; and staff and medical student training on diagnostic/clinical issues.

Feb. 96-Sep. 96 Contract Alcohol and Drug Education Instructor, Metropolitan Correctional Center (Federal Prison), San Diego, Ca. Provided drug abuse/addiction education instruction to Spanish-speaking inmates on a consulting contract basis. Course instruction based on biopsychosocial model of addiction.

Jul. 95-Feb. 96 Contract Examiner for WAIS-III/WMS-III National Standardization Project, The Psychological Corporation-Harcourt Brace Jovanovich and Directions in Research, San Diego, Ca. Neurocognitive assessments for national re-standardization project of the Wechsler Adult Intelligence Scale-III and Wechsler Memory Scale-III, Children's Memory Scale, Wechsler Individual Achievement Test and other neurocognitive instruments.

Aug. 95-Aug. 96 Psychology Intern, Bayview Psychiatric Hospital, Chula Vista, Ca. Provided individual, family, and group psychotherapy on an in-patient and out-patient basis. Facilitated psychotherapy with chronically mentally-ill patients. Stress management and relapse prevention workshops for chemically dependent patients, and dually-diagnosed (mentally-ill and chemically dependent) individuals). Further duties included, conducting psychological evaluations with hospitalized children, adolescents, and adults.

Aug. 94-Aug. 95 Psychology Intern, University of California, San Diego, Ca. Individual and group counseling; workshops on psychological issues pertinent to the college population; psychological intakes; and treatment planning.

Sep. 92-Sep. 93 Practicum Student, Psychological Services Center, San Diego, Ca. Psychological testing, treatment planning, intakes, community outreach, translation, and individual therapy in a long-term counseling center.

Case Manager, Mount Carmel Guild Family Resource Center, Jersey City, N.J. Case management of Division of Youth and Family Services referred clients; individual and family counseling related to parenting skills; and management of after-school program.

1988-1991 Counselor, Hudson Association for Retarded Citizens, Bayonne, N.J. Implementation of individual habilitation plans, and teaching of developmentally disabled persons.

## PAST TEACHING POSITIONS:

Fall 1998 Adjunct Professor of Psychology, Felician College, Lodi, N.J. Taught Introduction to Childhood Development within a biopsychosocial model.

Spring 1999 Adjunct Professor of Psychology, Felician College, Rutherford, N.J. Taught biopsychology.

Fall 1999 Adjunct Professor of Psychology, Felician College, Lodi, N.J. Taught biological psychology.

Feb. 96-Sep. 96 Contract Alcohol and Drug Education Instructor, Metropolitan Correctional Center (Federal Prison), San Diego, Ca. Provided drug abuse/addiction education instruction to Spanish-speaking inmates on a consulting contract basis. Course instruction based on biopsychosocial model of addiction.

PROFESSIONAL SOCIETY MEMBERSHIPS: American Psychological Association

## CLINICAL DRUG TRIALS:

1999-2000 A Twenty-Week, Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled Study Of The Efficacy, Tolerability And Safety Of Sertraline In The Treatment Of The Behavioral Manifestations Of Alzheimer's Disease In Outpatients Treated With Donezepil, Pfizer Pharmaceuticals, New York.

Doxazosin in the Treatment of Benign Prostatic Hyperplasia. An Open Baseline Controlled, Study in Hospital Urological Practice. Pfizer Pharmaceuticals, New York, NY.

1998-1999 A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Comparison of the Effects of Monotherapy (given morning vs. evening) with Doxazosin versus Terazosin on Office Blood Pressure, Twenty-four Hour Blood Pressure Control, Side Effect Profile in Patients with Stage I and II Primary Hypertension. Pfizer Pharmaceuticals.

A Double-Blind, Multicenter, Placebo-Controlled, , Parallel Comparison of the Effects of Doxazosin versus Lisinopril, Alone and in Combination with Hydrochloride, on Blood Pressure Control, Renal Function, and Side Effect Profile in Black Patients with Stage I and II Primary Hypertension. Pfizer Pharmaceuticals.

The Influence of Antihypertensive Therapy with either Doxazosin, Atenolol, or Placebo on Blood Pressure Control, Insulin Sensitivity, Lipid Profile, Cardiovascular Autonomic Function and Reactivity, Glycaemic Control and Side Effect Profile in Both Non-Diabetic Hypertensives and Hypertensives with Type II Diabetes Mellitus Treated with Glipizide. Pfizer Pharmaceuticals.

A Double-Blind, Double Dummy, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Doxazosin vs. Finasteride vs. Combination Therapy in the Symptomatic Treatment of Benign Prostatic Hyperplasia. Pfizer Pharmaceuticals.

1997-98 A Multi-Center Pilot Study To Examine The Clinical Effects of Cross Titration of Antipsychotics With Ziprasidone In Subjects With Schizophrenia Or Schizoaffective Disorder Followed By An Optional Extension Phase With Continued Ziprasidone Treatment. Pfizer Pharmaceuticals.

A Multi-Center Pilot Study To Examine The Clinical Effects of Cross Titration of Olanzapine With Ziprasidone In Subjects With Schizophrenia Or Schizoaffective Disorder Followed By An Optional Extension Phase With Continued Ziprasidone Treatment. Pfizer Pharmaceuticals.

A Multi-Center Pilot Study To Examine The Clinical Effects of Cross Titration of Risperidone With Ziprasidone In Subjects With Schizophrenia Or Schizoaffective Disorder Followed By An Optional Extension Phase With Continued Ziprasidone Treatment. Pfizer Pharmaceuticals.

1996 A Phase IV, Double-Blind, Placebo Controlled, Multi-Center Study of Sertraline in Outpatients with PTSD. Pfizer Pharmaceuticals.

A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study of Melameline in Patients with Probable Alzheimer's Disease with Long-Term Open-Label Extension. Parke-Davis Pharmaceuticals.

29060/494/495/497 A Double-Blind, Placebo Controlled, Flexible-Dosing Trial to Evaluate the Efficacy of Modified Release Paroxetine in the Treatment of Panic Disorder. SmithKline Beecham Pharmaceuticals.

An Open-Label Study to Evaluate the Safety and Efficacy of 1.5 mg b.i.d. (3mg/day) through 6 mg b.i.d. (12 mg/day) of Exelon in Patients with Mild to Severe Probable Alzheimer's Disease in the Community Setting. Sandoz Pharmaceuticals Corp.

1995 Open-Label Trial Evaluating the Safety and Tolerability of ICI 204, 636 (Seroquel) in the Treatment of Elderly Subjects with Selected Idiopathic and Organic Psychosis. Zeneca Pharmaceuticals.

1994 An Open-Label Study of Serzone (Nefazadone) in the Management of Patients with Symptoms of Depression in General Psychiatric Practices. Bristol-Myers Squibb Pharmaceuticals.

Clinical Research Associate, Safety Surveillance for Wellbutrin Sustained Release. Burroughs-Wellcome Co.

CP-88,059-1. An Eight Week, Double-Blind, Haloperidol-Controlled Study Evaluating the Safety and Efficacy of Oral CP-88,059-1 in the Maintenance Treatment of Outpatients with Schizophrenia or Schizoaffective Disorder and Alcohol or Cannibis Abuse/Dependence. Pfizer Pharmaceuticals.

CP-88,059-1. A Study of Safety and Efficacy of Several Different Doses of CP-88 vs. Different Doses of Haloperidol in the Treatment of Outpatient Schizophrenic Patients. Pfizer Pharmaceuticals.

M93-132. A Double-Blind Comparison of Sertindole and Haldol, of Safety, Efficacy, Quality of Life, and Relapse in Stable Schizophrenic Patients. Abbott Laboratories. M93-113, A Double-Blind, Placebo-Controlled Dose-Response Comparison of the Safety and Efficacy of Three Doses of Sertindole and Three Doses of Haldol in Schizophrenic Patients. Abbott Laboratories.

SAB-USA-25. Clinical Efficacy and Safety of Sabeluzole in the Treatment of Alzheimer's Disease. Janssen Research Foundation.

1993 Efficacy and Safety Study of Besipirdine in Patients with Alzheimer's Disease. Hoechst Roussel Pharmaceuticals.

Double-Blind Comparison of Three Doses of Tandospirone vs. Placebo in Outpatients with Major Depressive Disorder. Pfizer Pharmaceuticals.Double-Blind, Randomized, Controlled, Multiple Fixed- Dose and Dose Regimen Comparison of Seroquel and Haloperidol in the Prevention of Psychotic Relapse in Outpatients with Chronic or Subchronic Schizophrenia. Zeneca Pharmaceuticals Group.

An Open-Label Assessment of the Long-Term Safety of Sertindole in the Treatment of Patients with Schizophrenia and Other Psychotic Disorders, Protocol #m93061. Abbott Neuroscience Venture.

Clinical Research Associate. A Comparison of the Safety and Efficacy of Flexible Dose Levels of Sertraline and Nortriptyline in the Treatment of Depressed Elderly Outpatients. Pfizer Pharmaceuticals.

HONORS:

1990 Charles Kaden Memorial Award for Academic Excellence in Psychology-Rutgers University

1990 Phi Beta Kappa-Inducted Spring 1990

1987 West Point Military Academy Nominee